Clairus Technologies Licenses Molecular Diagnostic from UPenn to Study Steroid Responsiveness | GenomeWeb

NEW YORK, Nov. 13 - Clairus Technologies has struck a licensing agreement with the University of Pennsylvania to develop a genomics-based product that may help physicians learn whether steroids prescribed to treat an inflammatory disease are having the desired effect, a company official has told GenomeWeb.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.